[Brief Introduction of Seminar]

Nutritional solutions are evolving toward greater emphasis on palatability and ease of intake. In both pharmaceutical and dietary supplement sectors, taste and format have become key considerations in formulation development.

In addition, backed by years of research into the science of taste perception, our portfolio of flavor and taste solutions for solid and liquid drug products support better patient compliance.  

[Brief Introduction of Speaker]

Lay Kwan Goh is the Pharma Segment Lead for Health, Nutrition & Care, at dsm-firmenich, where she drives strategic growth and innovation of science-backed pharmaceutical solutions across key therapeutic areas in the Asia Pacific region. With 25 years of experience in global and regional marketing roles, Lay Kwan brings deep expertise in driving B2B businesses, customer engagement, and commercial strategy. She has led cross-functional teams across continents, launched successful go-to-market initiatives, and championed business transformation over the years. Lay Kwan is passionate about translating science into impact and building customer solutions that elevate patient health with safe and effective therapies worldwide.​

[Brief Introduction of Speaker]

Sultan Al Mansour is the CEO of All Care Group, a fully integrated healthcare ecosystem founded in 2009. The group comprises six specialized companies operating across clinical services, facility management, medical manufacturing, pharmaceutical distribution, and healthcare innovation. With a network of medical centers across Saudi Arabia’s key regions, a medical supplies factory, and a comprehensive distribution infrastructure, All Care Group plays a pivotal role in advancing national healthcare capabilities and regional access.

[주제 세부 소개]

Join us as we explore the innovative world of liposomal technology and how it is transforming nutrient delivery in the nutraceutical industry. This seminar will delve into the science behind liposomes—microscopic lipid-based vesicles—and their critical role in enhancing the stability, absorption, and bioavailability of active ingredients.

We will also highlight the importance of pharmacokinetics in designing more effective liposomal formulations that ensure targeted delivery and improved efficacy. Discover how this advanced delivery system is shaping the future of smarter, more efficient supplementation. 

[연사 소개]

Dr. Shiv holds a Master’s degree in Pharmacy from Rajiv Gandhi University of Health Sciences, Karnataka, and a Ph.D. in Pharmaceutical Sciences from Dr. H.S. Gour University, India. A recognized leader in the nutraceutical and herbal research space, he received the prestigious “Young Scientist” award for his contributions to pharma, biotech, and herbal drug research at the international level, honored by Johns Hopkins University (USA) and Colombo University (Sri Lanka).

Having traveled to 23 countries, Dr. Shiv brings a global perspective through his active participation in international expos and industry events across the USA, Europe, and Asia.​  

[Brief Introduction of Seminar]

K-HealthMIRAE Initiative is a Korean ARPA-H model that promotes innovative national R&D to overcome unconquered rare diseases. The HEART project will develop an N-of-1 clinically-based patient-tailored RNA therapy platform for fatal pediatric rare diseases, and the BEACON project will develop gene therapy for inherited retinal diseases. With KRW 17.5 billion invested in each project over 4.5 years, the project is expected to expand the number of diseases to which customized therapies can be applied and provide new therapeutic opportunities and hope for patients with rare diseases.

[Brief Introduction of Speaker]​

​Dr. Misun Park has over 25 years of experience in advanced biopharmaceuticals, regenerative medicine, and regulatory science. She conducted cardiovascular research at MFDS, Rutgers Medical School, and Columbia University. Currently, as Project Manager at the K-Health Future Diagnostics Initiative, she drives planning and execution of R&D strategies for patient-customized therapeutics to overcome rare diseases.​

[Brief Introduction of Seminar]

The current national cancer screening program in Korea is estimated to impact only about 50% of overall cancer incidence and mortality, highlighting its limited effectiveness. Moreover, conventional screening methods such as expensive imaging technologies or endoscopy raise concerns about health equity and accessibility for certain population groups. In contrast, liquid biopsy-based multi-cancer early detection (MCED) tests, which enable the detection of multiple cancers through a single blood draw, have the potential to dramatically improve patient accessibility and convenience. To implement MED, it is essential to improve their technical performance, clearly define their role with existing screening programs, and establish appropriate regulatory frameworks.

[Brief Introduction of Speaker]​

Tae-You Kim, MD, PhD is the co-founder and CEO of IMBdx Inc., a precision oncology company specializing in liquid biopsy. He is also a professor in the Department of Internal Medicine at Seoul National University Hospital, and has served as a faculty member at SNU College of Medicine since 2000.

Dr. Kim has held several prominent leadership roles, including Director of SNU Cancer Hospital (2015–2017), President of the Korea Genome Organization (2017), Chairman of the Korean Society of Medical Oncology (2018–2020) and of the Korea Cancer Association (2022–2024). He has been awarded several academic prizes for his contribution to the oncology. Dr. Kim has authored over 400 peer-reviewed publications and has delivered more than 200 invited lectures.​